NGM313 is an agonistic antibody that promotes beneficial metabolic activity by activating receptors responsible for the regulation of body weight, triglycerides, cholesterol and insulin sensitivity. San Francisco-based NGM Bio believes that the antibody has the potential to cause meaningful body weight loss and improved insulin sensitivity.
The study encompasses a randomized, double-blind, placebo-controlled trial to investigate the safety, tolerability and pharmacokinetic profile of NGM313. The trial will also measure a variety of biomarkers associated with metabolic regulation.
Kenilworth, N.J.-based pharmaceutical company Merck has an exclusive, one-time option to license the antibody following completion of a human proof of concept study.
Results of the trial are expected in 2017.
More articles on supply chain:
NuVasive acquires Biotronic for $98M
Medtronic to launch new surgical robot by 2019
Vertera cervical fusion device implanted for first time
